Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TSN

Gene summary for TSN

Gene summary.

Gene information	Species	Human
	Gene symbol	TSN
	Gene ID	7247
	Gene name	translin
	Gene Alias	BCLF-1
	Cytomap	2q14.3
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	B3KRM8

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
7247	TSN	LZE2T	Human	Esophagus	ESCC	1.59e-06	6.31e-01	0.082
7247	TSN	LZE4T	Human	Esophagus	ESCC	2.82e-15	5.49e-01	0.0811
7247	TSN	LZE5T	Human	Esophagus	ESCC	4.63e-02	2.43e-01	0.0514
7247	TSN	LZE7T	Human	Esophagus	ESCC	8.07e-11	8.11e-01	0.0667
7247	TSN	LZE8T	Human	Esophagus	ESCC	2.49e-05	2.78e-01	0.067
7247	TSN	LZE20T	Human	Esophagus	ESCC	3.48e-03	1.95e-01	0.0662
7247	TSN	LZE22D1	Human	Esophagus	HGIN	7.11e-03	9.13e-02	0.0595
7247	TSN	LZE22T	Human	Esophagus	ESCC	4.76e-03	5.49e-01	0.068
7247	TSN	LZE24T	Human	Esophagus	ESCC	2.69e-21	4.09e-01	0.0596
7247	TSN	LZE21T	Human	Esophagus	ESCC	5.63e-05	3.23e-01	0.0655
7247	TSN	LZE6T	Human	Esophagus	ESCC	1.14e-14	3.18e-01	0.0845
7247	TSN	P1T-E	Human	Esophagus	ESCC	7.41e-09	2.35e-01	0.0875
7247	TSN	P2T-E	Human	Esophagus	ESCC	3.26e-32	5.99e-01	0.1177
7247	TSN	P4T-E	Human	Esophagus	ESCC	1.28e-37	8.04e-01	0.1323
7247	TSN	P5T-E	Human	Esophagus	ESCC	5.12e-28	5.25e-01	0.1327
7247	TSN	P8T-E	Human	Esophagus	ESCC	1.63e-29	4.87e-01	0.0889
7247	TSN	P9T-E	Human	Esophagus	ESCC	2.38e-10	2.09e-01	0.1131
7247	TSN	P10T-E	Human	Esophagus	ESCC	5.38e-66	1.04e+00	0.116
7247	TSN	P11T-E	Human	Esophagus	ESCC	1.67e-21	8.62e-01	0.1426
7247	TSN	P12T-E	Human	Esophagus	ESCC	9.28e-91	1.68e+00	0.1122

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:002260410	Cervix	CC	regulation of cell morphogenesis	84/2311	309/18723	1.00e-12	4.29e-10	84
GO:00510566	Cervix	CC	regulation of small GTPase mediated signal transduction	75/2311	302/18723	1.54e-09	1.74e-07	75
GO:00163587	Cervix	CC	dendrite development	58/2311	243/18723	4.52e-07	1.76e-05	58
GO:00160498	Cervix	CC	cell growth	92/2311	482/18723	1.16e-05	2.49e-04	92
GO:00609965	Cervix	CC	dendritic spine development	28/2311	99/18723	1.61e-05	3.15e-04	28
GO:00068987	Cervix	CC	receptor-mediated endocytosis	53/2311	244/18723	2.52e-05	4.29e-04	53
GO:00301008	Cervix	CC	regulation of endocytosis	47/2311	211/18723	3.65e-05	5.82e-04	47
GO:00458077	Cervix	CC	positive regulation of endocytosis	27/2311	100/18723	5.55e-05	8.10e-04	27
GO:00725836	Cervix	CC	clathrin-dependent endocytosis	16/2311	47/18723	9.56e-05	1.25e-03	16
GO:00459277	Cervix	CC	positive regulation of growth	53/2311	259/18723	1.33e-04	1.64e-03	53
GO:00015588	Cervix	CC	regulation of cell growth	77/2311	414/18723	1.40e-04	1.70e-03	77
GO:00161977	Cervix	CC	endosomal transport	48/2311	230/18723	1.65e-04	1.97e-03	48
GO:00609984	Cervix	CC	regulation of dendritic spine development	18/2311	61/18723	2.84e-04	3.07e-03	18
GO:00995322	Cervix	CC	synaptic vesicle endosomal processing	6/2311	10/18723	4.73e-04	4.68e-03	6
GO:00303077	Cervix	CC	positive regulation of cell growth	36/2311	166/18723	4.84e-04	4.75e-03	36
GO:00486386	Cervix	CC	regulation of developmental growth	61/2311	330/18723	7.69e-04	6.85e-03	61
GO:00605606	Cervix	CC	developmental growth involved in morphogenesis	46/2311	234/18723	8.82e-04	7.63e-03	46
GO:19052442	Cervix	CC	regulation of modification of synaptic structure	6/2311	13/18723	2.78e-03	1.87e-02	6
GO:00484883	Cervix	CC	synaptic vesicle endocytosis	16/2311	62/18723	2.87e-03	1.91e-02	16
GO:01402383	Cervix	CC	presynaptic endocytosis	16/2311	62/18723	2.87e-03	1.91e-02	16

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

TF	Cell Type	Tissue	Disease Stage	Target Gene	RSS	Regulon Activity
TSN	CD8TCM	Colorectum	AD	CHI3L2,SPARCL1,TIPRL, etc.	7.32e-02
TSN	MAST	Colorectum	ADJ	CHI3L2,SPARCL1,TIPRL, etc.	9.13e-02
TSN	CD8TCM	Colorectum	ADJ	CHI3L2,SPARCL1,TIPRL, etc.	3.24e-02
TSN	CD8TCM	Colorectum	FAP	CHI3L2,SPARCL1,TIPRL, etc.	5.36e-02
TSN	GC	Colorectum	MSI-H	CHI3L2,SPARCL1,TIPRL, etc.	7.18e-02
TSN	GC	Colorectum	SER	CHI3L2,SPARCL1,TIPRL, etc.	3.22e-02
TSN	DIFF	Esophagus	Healthy	MSMO1,NMU,RHEB, etc.	1.12e-01

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

TSN

insertion

In_Frame_Ins

novel

c.453_453+1insTCTTTATTA

p.Ser152_Arg153insLeuLeuSer

p.S152_R153insLLS

Q15631

protein_coding

TCGA-A8-A09T-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

TSN

SNV

Missense_Mutation

c.464C>A

p.Ser155Tyr

p.S155Y

Q15631

protein_coding

deleterious(0)

probably_damaging(0.928)

TCGA-AD-5900-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

TSN

SNV

Missense_Mutation

c.475N>A

p.Val159Met

p.V159M

Q15631

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-CA-6716-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Chemotherapy

oxaliplatin

TSN

SNV

Missense_Mutation

c.268N>T

p.His90Tyr

p.H90Y

Q15631

protein_coding

deleterious(0.01)

possibly_damaging(0.895)

TCGA-AP-A051-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

TSN

SNV

Missense_Mutation

novel

c.586N>A

p.Asp196Asn

p.D196N

Q15631

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AP-A0LM-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

cisplatin

TSN

SNV

Missense_Mutation

novel

c.634N>A

p.Leu212Ile

p.L212I

Q15631

protein_coding

tolerated(0.22)

possibly_damaging(0.748)

TCGA-AX-A05Z-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

TSN

SNV

Missense_Mutation

novel

c.362N>G

p.Glu121Gly

p.E121G

Q15631

protein_coding

deleterious(0.03)

possibly_damaging(0.664)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

TSN

SNV

Missense_Mutation

c.622N>T

p.Val208Leu

p.V208L

Q15631

protein_coding

deleterious(0)

probably_damaging(0.953)

TCGA-B5-A0JY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

TSN

SNV

Missense_Mutation

rs774578869

c.524A>G

p.Asn175Ser

p.N175S

Q15631

protein_coding

tolerated(0.67)

benign(0.027)

TCGA-B5-A0JZ-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

TSN

SNV

Missense_Mutation

c.34N>A

p.Gly12Ser

p.G12S

Q15631

protein_coding

tolerated(0.75)

benign(0.003)

TCGA-B5-A11E-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1